Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bremelanotide - Palatin Technologies

Drug Profile

Bremelanotide - Palatin Technologies

Alternative Names: PT-141; Rekynda™; Vyleesi

Latest Information Update: 10 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona
  • Developer AMAG Pharmaceuticals; Palatin Technologies
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Female sexual dysfunction

Highest Development Phases

  • Marketed Female sexual dysfunction
  • Discontinued Erectile dysfunction; Haemorrhagic shock; Vascular disorders

Most Recent Events

  • 01 Sep 2019 Launched for Female sexual dysfunction in USA (SC) - - First global launch
  • 25 Jun 2019 Discontinued - Phase-I for Erectile dysfunction in USA (SC) (Palatin technologies pipeline, June 2019)
  • 21 Jun 2019 AMAG Pharmaceuticals intends to launch bremelanotide in USA in September 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top